Abstract
Increasing rates of obesity and its comorbidities continue to place a burden on individuals and health systems. Lifestyle interventions, although effective, are not always successful in long term management. The use of existing medicinal strategies, such as sibutramine and orlistat have not been very successful due to their own limitations. Semaglutide is a glucagon-like peptide-1 analogue that has been utilized in type 2 diabetes mellitus treatment. Its use in weight management has been recently explored in several studies. A review of literature can provide insight into whether semaglutide is a potential avenue for long term and sustainable weight loss. All studies reviewed identified that study participants on semaglutide experienced a significantly higher overall weight loss than placebo and most other comparison treatments. There were gastrointestinal adverse events recorded in most studies, but these did not seem to have an impact on the overall weight loss. Semaglutide provides a promising avenue for weight loss in obese and overweight individuals, although further research on management avenues for the GI events may ensure long term and sustained use. Key words: semaglutide, obesity, weight loss
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: World Family Medicine Journal /Middle East Journal of Family Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
